Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
Sumanta K. Pal(City of Hope), Laurence Albigès(Institut Gustave Roussy), Piotr Tomczak(Poznan University of Medical Sciences), Cristina Suárez(Vall d'Hebron Hospital Universitari), Martin H. Voss(Memorial Sloan Kettering Cancer Center), Guillermo de Velasco(Research Institute Hospital 12 de Octubre), Jad Chahoud(Moffitt Cancer Center), Anastasia Mochalova, Giuseppe Procopio(Fondazione IRCCS Istituto Nazionale dei Tumori), Hakim Mahammedi(Centre Jean Perrin), Friedemann Zengerling(University Hospital Ulm), Chan Kim(CHA University), Takahiro Osawa(Hokkaido University Hospital), Martín Ángel(Instituto Alexander Fleming), Suyasha Gupta, Omara Khan(Roche (United Kingdom)), Guillaume Bergthold(Roche (Switzerland)), Bo Liu, Melania Kalaitzidou(Roche (United Kingdom)), Mahrukh Huseni, Christian Scheffold(Exelixis (United States)), Thomas Powles(Queen Mary University of London), Toni K. Choueiri(Dana-Farber Cancer Institute)
Cited by 192Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis